Definium Therapeutics (DFTX) Assets Average (2022 - 2026)
Definium Therapeutics (DFTX) posted quarterly Assets Average of $420.7 million for Q1 2026, up 45.7% year-over-year from $288.7 million in Q1 2025, and up 24.28% quarter-over-quarter from $338.5 million in Q4 2025.
Definium Therapeutics (DFTX) Assets Average (2022 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has reported Assets Average for 5 consecutive years, with $420.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 45.7% year-over-year to $420.7 million; the TTM figure through Mar 2026 stood at $420.7 million (up 45.7% YoY), while the FY2025 annual figure was $371.1 million, up 73.95% from the prior year.
- Assets Average grew to $420.7 million in Q1 2026 per DFTX's latest filing, from $338.5 million in the prior quarter.
- Across five years, Assets Average topped out at $420.7 million in Q1 2026 and bottomed at $133.0 million in Q4 2023.
- Historically, Assets Average has averaged $227.3 million across 5 years, with a median of $200.0 million in 2024.
- Annual changes were most pronounced in 2023 — Assets Average fell 24.17% — and 2024, when it soared 133.72%.
- Definium Therapeutics' Assets Average stood at $175.4 million in 2022, then dropped by 24.17% to $133.0 million in 2023, then jumped by 133.72% to $311.0 million in 2024, then increased by 8.86% to $338.5 million in 2025, then rose by 24.28% to $420.7 million in 2026.
- Business Quant data shows DFTX's Assets Average at $420.7 million in Q1 2026, $338.5 million in Q4 2025, and $251.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Definium Therapeutics | 4.72 Bn | 4.72 Bn | - | 757.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 757.10 Mn |
| Mar 31, 2026 | 420.70 Mn |
| Dec 31, 2025 | 338.51 Mn |
| Sep 30, 2025 | 251.00 Mn |
| Jun 30, 2025 | 270.21 Mn |
| Mar 31, 2025 | 288.74 Mn |
| Dec 31, 2024 | 310.96 Mn |
| Sep 30, 2024 | 293.96 Mn |
| Jun 30, 2024 | 271.84 Mn |
| Mar 31, 2024 | 200.04 Mn |
| Dec 31, 2023 | 133.05 Mn |
| Sep 30, 2023 | 141.82 Mn |
| Jun 30, 2023 | 148.81 Mn |
| Mar 31, 2023 | 162.76 Mn |
| Dec 31, 2022 | 175.45 Mn |
| Sep 30, 2022 | 157.59 Mn |
| Jun 30, 2022 | 141.76 Mn |
| Mar 31, 2022 | 156.62 Mn |